← Leaderboards
Pradeep Singh
Seattle Children'S Hospital
$15,010,155
Attributed
$21,099,400
Total exposure
16
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.3M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$32,046,424 · 17
FDA$2,309,802 · 1
By mechanism
R01$14,007,736 · 7
P30$12,316,638 · 6
UM1$4,752,240 · 1
K24$1,628,316 · 1
R56$1,149,312 · 2
K08$501,984 · 1
Top collaborators
- Christopher Hooper Goss10 shared
- James Edward Bruce9 shared
- Mary J Emond5 shared
- Colin C Manoil5 shared
- Bonnie W Ramsey4 shared
- Jerry A Nick3 shared
Most similar at Seattle Children'S Hospital
Same institution · by research overlap
- Christopher Hooper Goss$12,695,799
- Lakshmi Rajagopal$23,879,900
- Jerry A Nick$4,265,868
Others in their field
Top investigators on “Cystic Fibrosis”
- John F Engelhardt · University Of Iowa$42,933,706
- Michael R Knowles · University Of North Carolina Chapel Hill$30,250,682
- David A Stoltz · University Of Iowa$25,455,359
- Joseph Zabner · University Of Iowa$25,382,103
- Paul B McCray · University Of Iowa$25,146,293
- Richard C Boucher · University Of North Carolina Chapel Hill$24,890,955
Research focus
Cystic FibrosisCystic Fibrosis PatientsLinkChronicPseudomonas AeruginosaInfectionLungIn VivoResearch PersonnelAffectMicrobiologyPhenotypeFundingAntibioticsResistanceBacteriaOrganismProgramsSputumPathogenesisClinical ResearchInflammationResourcesNovel Therapeutics
Grant awards (63)
A Phase 1b, Multi-center Study of IV Gallium Nitrate in Patients with Cystic Fibrosis who are colonized with Nontuberculosis Mycobacterium (The ABATE Study).$739,415
R01 · FY2025 · FD
Pilot and Feasibility Program$494,315
P30 · FY2025 · DK · contact PI
Prevalence, Consequences and Mechanisms of Antibiotic Heteroresistance in Cystic Fibrosis$429,007
R01 · FY2025 · HL · contact PI
Cystic Fibrosis Translational Research in the Post-CFTR Modulator Era$1,209,483
P30 · FY2024 · DK
Prevalence, Consequences and Mechanisms of Antibiotic Heteroresistance in Cystic Fibrosis$492,958
R01 · FY2024 · HL · contact PI
Pilot and Feasibility program$426,489
P30 · FY2024 · DK · contact PI
Cystic Fibrosis Translational Research in the Post-CFTR Modulator Era$1,211,277
P30 · FY2023 · DK
A Phase 1b, Multi-center Study of IV Gallium Nitrate in Patients with Cystic Fibrosis who are colonized with Nontuberculosis Mycobacterium (The ABATE Study).$716,405
R01 · FY2023 · FD
Prevalence, Consequences and Mechanisms of Antibiotic Heteroresistance in Cystic Fibrosis$590,688
R01 · FY2023 · HL · contact PI
Pilot and Feasibility program$426,489
P30 · FY2023 · DK · contact PI
Cystic Fibrosis Translational Research in the Post-CFTR Modulator Era$1,213,036
P30 · FY2022 · DK
Field Study to Understand Progression of Chronic Airway Infection$671,700
R01 · FY2022 · HL · contact PI
Prevalence, Consequences and Mechanisms of Antibiotic Heteroresistance in Cystic Fibrosis$645,617
R01 · FY2022 · HL · contact PI
Pilot and Feasibility program$426,489
P30 · FY2022 · DK · contact PI
Cystic Fibrosis Translational Research in the Post-CFTR Modulator Era$1,214,759
P30 · FY2021 · DK
Field Study to Understand Progression of Chronic Airway Infection$713,558
R01 · FY2021 · HL · contact PI
Pilot and Feasibility program$426,489
P30 · FY2021 · DK · contact PI
Cystic Fibrosis Translational Research in the Post-CFTR Modulator Era$1,230,099
P30 · FY2020 · DK
A Phase 1b, Multi-center Study of IV Gallium Nitrate in Patients with Cystic Fibrosis who are colonized with Nontuberculosis Mycobacterium (The ABATE Study).$853,982
R01 · FY2020 · FD
Field Study to Understand Progression of Chronic Airway Infection$746,211
R01 · FY2020 · HL · contact PI
Pilot and Feasibility program$426,489
P30 · FY2020 · DK · contact PI
Translational Research Center to Expedite Novel Therapies in Cystic Fibrosis$1,212,966
P30 · FY2019 · DK
Field Study to Understand Progression of Chronic Airway Infection$765,679
R01 · FY2019 · HL · contact PI
Pilot and Feasibility Program$394,462
P30 · FY2019 · DK · contact PI
Studies on bacterial populations and therapeutics for CF lung infections$150,206
K24 · FY2019 · HL · contact PI
Translational Research Center to Expedite Novel Therapies in Cystic Fibrosis$1,212,966
P30 · FY2018 · DK
Clinical Effects of Evolved Variation in Infecting Bacterial Populations$673,705
R56 · FY2018 · HL · contact PI
Studies on bacterial populations and therapeutics for CF lung infections$150,206
K24 · FY2018 · HL · contact PI
Studies on bacterial populations and therapeutics for CF lung infections$150,206
K24 · FY2017 · HL · contact PI
Proof of Principle Evaluation of IV Gallium Nitrate in Patients with CF$92,308
UM1 · FY2017 · HL
Proof of Principle Evaluation of IV Gallium Nitrate in Patients with CF$1,805,147
UM1 · FY2016 · HL
Investigating treatment resistance mechanisms in chronic bacterial infections$594,236
R01 · FY2016 · AI · contact PI
Pilot and Feasibility Program$395,415
P30 · FY2016 · DK · contact PI
Studies on bacterial populations and therapeutics for CF lung infections$150,206
K24 · FY2016 · HL · contact PI
Proof of Principle Evaluation of IV Gallium Nitrate in Patients with CF$1,853,439
UM1 · FY2015 · HL
Investigating treatment resistance mechanisms in chronic bacterial infections$594,236
R01 · FY2015 · AI · contact PI
Pilot and Feasibility Program$395,415
P30 · FY2015 · DK · contact PI
Studies on bacterial populations and therapeutics for CF lung infections$150,206
K24 · FY2015 · HL · contact PI
Investigating treatment resistance mechanisms in chronic bacterial infections$594,936
R01 · FY2014 · AI · contact PI
Investigating bacterial-host interactions driving CF Pulmonary Exacerbations$398,622
R01 · FY2014 · HL · contact PI
Studies on bacterial populations and new therapeutics for CF lung infections$176,169
K24 · FY2014 · HL · contact PI
Proof of Principle Evaluation of IV Gallium Nitrate in Patients with CF$1,001,346
UM1 · FY2013 · HL
Investigating treatment resistance mechanisms in chronic bacterial infections$559,240
R01 · FY2013 · AI · contact PI
Investigating bacterial-host interactions driving CF Pulmonary Exacerbations$388,691
R01 · FY2013 · HL · contact PI
Studies on bacterial populations and new therapeutics for CF lung infections$176,169
K24 · FY2013 · HL · contact PI
Investigating treatment resistance mechanisms in chronic bacterial infections$604,576
R01 · FY2012 · AI · contact PI
Investigating bacterial-host interactions driving CF Pulmonary Exacerbations$406,096
R01 · FY2012 · HL · contact PI
Studies on bacterial populations and new therapeutics for CF lung infections$176,169
K24 · FY2012 · HL · contact PI
Using infecting population dynamics to understand chronic cystic fibrosis infecti$475,607
R56 · FY2011 · AI · contact PI
Investigating bacterial-host interactions driving CF Pulmonary Exacerbations$404,861
R01 · FY2011 · HL · contact PI
Studies on bacterial populations and new therapeutics for CF lung infections$176,169
K24 · FY2011 · HL · contact PI
Gallium, a potential new therapeutic for CF airway infections$424,124
R01 · FY2010 · HL · contact PI
Studies on bacterial populations and new therapeutics for CF lung infections$172,610
K24 · FY2010 · HL · contact PI
Gallium, a potential new therapeutic for CF airway infections$483,293
R01 · FY2009 · HL · contact PI
Biofilm Detachment Mechanisms in Chronic Lung Infections$295,832
R01 · FY2007 · HL · contact PI
Biofilm Detachment Mechanisms in Chronic Lung Infections$303,773
R01 · FY2006 · HL · contact PI
Biofilm Detachment Mechanisms in Chronic Lung Infections$274,224
R01 · FY2005 · HL
Biofilm Detachment Mechanisms in Chronic Lung Infections$20,776
R01 · FY2005 · HL
Biofilm Detachment Mechanisms in Chronic Lung Infections$295,000
R01 · FY2004 · HL
AIRWAY DEFENSES AGAINST BIOFILM INFECTIONS$125,496
K08 · FY2003 · HL
AIRWAY DEFENSES AGAINST BIOFILM INFECTIONS$125,496
K08 · FY2002 · HL
AIRWAY DEFENSES AGAINST BIOFILM INFECTIONS$125,496
K08 · FY2001 · HL
AIRWAY DEFENSES AGAINST BIOFILM INFECTIONS$125,496
K08 · FY2000 · HL